LATHAM, N.Y. / Mar 31, 2025 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company’s Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day.
Virtual Cardiovascular Investor Event
Date: Wednesday, April 2, 2025
Time: 9:00am ET
Duration: 60 minutes
Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=cedf6b19b1
Event Overview
AngioDynamics will provide investors a deeper dive into the cardiovascular technology portfolio and strategic vision.
The event will be webcast and can be accessed through the "Investors" section of the AngioDynamics website at www.angiodynamics.com.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
| Last Trade: | US$8.73 |
| Daily Change: | -0.33 -3.64 |
| Daily Volume: | 423,799 |
| Market Cap: | US$354.700M |
July 28, 2025 July 23, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
